Burjeel Holdings, a leading healthcare provider in the UAE, has reported a solid performance for the first half of 2024, with its net profit rising by 5.9% to AED 238 million. This growth, calculated after excluding one-off items and taxes, highlights the company’s robust financial health and strategic resilience in a competitive market.
The Abu Dhabi Securities Exchange (ADX)-a listed company has attributed this profit increase to a combination of factors, primarily the significant rise in revenue and the reduction in finance and amortization costs. Burjeel Holdings recorded a 10.4% growth in revenue, bringing in AED 2.4 billion during the first six months of the year.
A closer look at the revenue breakdown reveals that the outpatient services segment saw a notable increase, contributing an additional AED 137 million to the overall revenue. Inpatient services also performed strongly, with an AED 82 million increase, reflecting Burjeel’s comprehensive approach to healthcare delivery and patient care.
The company’s management pointed out that this revenue growth was achieved despite facing higher direct costs, particularly those related to ongoing investments in oncology. These investments are part of Burjeel’s long-term strategy to enhance its oncology services, positioning the group to meet the anticipated future demand for cancer treatments and care.
The continued focus on oncology reflects Burjeel’s commitment to expanding its specialized healthcare offerings and catering to the evolving needs of the UAE’s population.
The group’s strategy of reinvesting in its facilities and services has enabled it to maintain a competitive edge while ensuring that it can provide high-quality care across a range of medical disciplines.
Burjeel Holdings’ ability to sustain growth despite the rising costs associated with these investments underscores its strong operational efficiency and strategic foresight. As the UAE healthcare sector evolves, Burjeel leverages its strengths, focusing on growth and expansion in the coming years.
The company’s performance in H1 2024 sets a positive tone for the remainder of the year, as it continues to build on its success and drive forward its mission of providing exceptional healthcare services across the region.
